B-ALL-话题@MedSci

#B-ALL#

19篇内容 | 2565人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1423267, encodeId=2412142326e86, content=<a href='/topic/show?id=18f43131be' target=_blank style='color:#2F92EE;'>#B-ALL#</a>, objectTitle=Blood：尼洛替尼联合PD-L1阻滞可逆转CD4+T细胞耗竭预防B-ALL复发, objectType=article, longId=736337, objectId=b0e3e36337f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b0e3e36337f3, replyNumber=0, likeNumber=102, createdTime=2022-08-21, rootId=0, userName=chenzhuanggui, userId=7c123763345, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b0e3e36337f3, moduleTitle=Blood：尼洛替尼联合PD-L1阻滞可逆转CD4+T细胞耗竭预防B-ALL复发, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b0e3e36337f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1423266, encodeId=8ec2142326680, content=<a href='/topic/show?id=18f43131be' target=_blank style='color:#2F92EE;'>#B-ALL#</a>, objectTitle=Blood：采用CD19/22 CAR T细胞治疗儿童和年轻成人B-ALL, objectType=article, longId=735519, objectId=bdfbe3551900, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bdfbe3551900, replyNumber=0, likeNumber=103, createdTime=2022-08-12, rootId=0, userName=chenzhuanggui, userId=7c123763345, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bdfbe3551900, moduleTitle=Blood：采用CD19/22 CAR T细胞治疗儿童和年轻成人B-ALL, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bdfbe3551900)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1423265, encodeId=b8ac1423265c3, content=<a href='/topic/show?id=18f43131be' target=_blank style='color:#2F92EE;'>#B-ALL#</a>, objectTitle=J Clin Oncol：博纳吐单抗诱导巩固+POMP维持治疗Ph染色体阴性B-ALL老年患者的疗效, objectType=article, longId=299130, objectId=317729913045, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=317729913045, replyNumber=0, likeNumber=125, createdTime=2022-02-20, rootId=0, userName=chenzhuanggui, userId=7c123763345, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=317729913045, moduleTitle=J Clin Oncol：博纳吐单抗诱导巩固+POMP维持治疗Ph染色体阴性B-ALL老年患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=317729913045)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1423264, encodeId=1426142326459, content=<a href='/topic/show?id=18f43131be' target=_blank style='color:#2F92EE;'>#B-ALL#</a>, objectTitle=J Clin Oncol：博纳吐单抗无反应和高疾病负荷提示，B-ALL患者采用CD19-CAR治疗的预后不良, objectType=article, longId=220543, objectId=20ce220543ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=20ce220543ab, replyNumber=0, likeNumber=0, createdTime=2021-11-19, rootId=0, userName=chenzhuanggui, userId=7c123763345, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=20ce220543ab, moduleTitle=J Clin Oncol：博纳吐单抗无反应和高疾病负荷提示，B-ALL患者采用CD19-CAR治疗的预后不良, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=20ce220543ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1423263, encodeId=fb601423263d3, content=<a href='/topic/show?id=18f43131be' target=_blank style='color:#2F92EE;'>#B-ALL#</a>, objectTitle=Nat Med：双重靶向CART细胞对复发或难治性B-ALL儿童和年轻成人患者疗效分析, objectType=article, longId=218616, objectId=a035218616b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a035218616b0, replyNumber=0, likeNumber=131, createdTime=2021-10-16, rootId=0, userName=chenzhuanggui, userId=7c123763345, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a035218616b0, moduleTitle=Nat Med：双重靶向CART细胞对复发或难治性B-ALL儿童和年轻成人患者疗效分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a035218616b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1423262, encodeId=206114232625c, content=<a href='/topic/show?id=18f43131be' target=_blank style='color:#2F92EE;'>#B-ALL#</a>, objectTitle=Blood：分子分类可改善BCR-ABL1阴性B-ALL成人患者的风险评估, objectType=article, longId=217625, objectId=ef7421e625f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ef7421e625f6, replyNumber=0, likeNumber=77, createdTime=2021-09-26, rootId=0, userName=chenzhuanggui, userId=7c123763345, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ef7421e625f6, moduleTitle=Blood：分子分类可改善BCR-ABL1阴性B-ALL成人患者的风险评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ef7421e625f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1423261, encodeId=d02614232616f, content=<a href='/topic/show?id=18f43131be' target=_blank style='color:#2F92EE;'>#B-ALL#</a>, objectTitle=J Clin Oncol：新型二代CD19-CAR T细胞治疗复发/难治性B-ALL成人患者的效果和安全性, objectType=article, longId=216567, objectId=da4821656e3b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=da4821656e3b, replyNumber=0, likeNumber=92, createdTime=2021-09-03, rootId=0, userName=chenzhuanggui, userId=7c123763345, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=da4821656e3b, moduleTitle=J Clin Oncol：新型二代CD19-CAR T细胞治疗复发/难治性B-ALL成人患者的效果和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=da4821656e3b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1423260, encodeId=6c4114232605a, content=<a href='/topic/show?id=18f43131be' target=_blank style='color:#2F92EE;'>#B-ALL#</a>, objectTitle=Blood：抗CD19 CAR T细胞治疗后病情进展的B-ALL成人患者的干预措施和临床预后, objectType=article, longId=216349, objectId=c86e216349f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c86e216349f4, replyNumber=0, likeNumber=95, createdTime=2021-08-28, rootId=0, userName=chenzhuanggui, userId=7c123763345, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c86e216349f4, moduleTitle=Blood：抗CD19 CAR T细胞治疗后病情进展的B-ALL成人患者的干预措施和临床预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c86e216349f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1423259, encodeId=089914232599a, content=<a href='/topic/show?id=18f43131be' target=_blank style='color:#2F92EE;'>#B-ALL#</a>, objectTitle=J Clin Oncol：人源CD19 CAR T细胞可使复发或难治性B-ALL患者获得持久的缓解, objectType=article, longId=213190, objectId=1a3a21319035, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1a3a21319035, replyNumber=0, likeNumber=134, createdTime=2021-06-26, rootId=0, userName=chenzhuanggui, userId=7c123763345, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1a3a21319035, moduleTitle=J Clin Oncol：人源CD19 CAR T细胞可使复发或难治性B-ALL患者获得持久的缓解, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1a3a21319035)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1423258, encodeId=53461423258a2, content=<a href='/topic/show?id=18f43131be' target=_blank style='color:#2F92EE;'>#B-ALL#</a>, objectTitle=Bone Marrow Transplant：供体源性抗CD19的CAR-T细胞疗法可安全有效的治疗异体造血干细胞移植后复发的B-ALL, objectType=article, longId=210740, objectId=e5eb210e403b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e5eb210e403b, replyNumber=0, likeNumber=72, createdTime=2021-05-03, rootId=0, userName=chenzhuanggui, userId=7c123763345, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e5eb210e403b, moduleTitle=Bone Marrow Transplant：供体源性抗CD19的CAR-T细胞疗法可安全有效的治疗异体造血干细胞移植后复发的B-ALL, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e5eb210e403b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1423257, encodeId=e0b3142325e06, content=<a href='/topic/show?id=18f43131be' target=_blank style='color:#2F92EE;'>#B-ALL#</a>, objectTitle=Blood：影响B-ALL患者博纳吐单抗治疗效果的肿瘤内外标志物, objectType=article, longId=200711, objectId=6fc9200e1160, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6fc9200e1160, replyNumber=0, likeNumber=94, createdTime=2020-09-17, rootId=0, userName=chenzhuanggui, userId=7c123763345, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6fc9200e1160, moduleTitle=Blood：影响B-ALL患者博纳吐单抗治疗效果的肿瘤内外标志物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6fc9200e1160)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1423256, encodeId=d22814232560d, content=<a href='/topic/show?id=18f43131be' target=_blank style='color:#2F92EE;'>#B-ALL#</a>, objectTitle=Blood：IKAROS和CK2调控高危型B-ALL的BCL-XL表达和化疗敏感性, objectType=article, longId=195267, objectId=dea919526ed5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dea919526ed5, replyNumber=0, likeNumber=90, createdTime=2020-06-05, rootId=0, userName=chenzhuanggui, userId=7c123763345, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dea919526ed5, moduleTitle=Blood：IKAROS和CK2调控高危型B-ALL的BCL-XL表达和化疗敏感性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dea919526ed5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1423255, encodeId=c81e14232559a, content=<a href='/topic/show?id=18f43131be' target=_blank style='color:#2F92EE;'>#B-ALL#</a>, objectTitle=Blood：B-ALL超二倍体细胞有丝分裂和染色体缺陷的分子机制, objectType=article, longId=193404, objectId=740319340482, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=740319340482, replyNumber=0, likeNumber=88, createdTime=2020-05-04, rootId=0, userName=chenzhuanggui, userId=7c123763345, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=740319340482, moduleTitle=Blood：B-ALL超二倍体细胞有丝分裂和染色体缺陷的分子机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=740319340482)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1423254, encodeId=235c1423254f2, content=<a href='/topic/show?id=18f43131be' target=_blank style='color:#2F92EE;'>#B-ALL#</a>, objectTitle=Blood：减小低复发风险B-ALL患儿的化疗强度可改善预后, objectType=article, longId=187701, objectId=053a18e70172, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=053a18e70172, replyNumber=0, likeNumber=96, createdTime=2020-02-10, rootId=0, userName=chenzhuanggui, userId=7c123763345, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=053a18e70172, moduleTitle=Blood：减小低复发风险B-ALL患儿的化疗强度可改善预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=053a18e70172)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1423253, encodeId=b034142325332, content=<a href='/topic/show?id=18f43131be' target=_blank style='color:#2F92EE;'>#B-ALL#</a>, objectTitle=Blood： CD19特异性CAR T细胞疗法治疗R/R B-ALL, objectType=article, longId=185565, objectId=07da185565a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=07da185565a3, replyNumber=0, likeNumber=151, createdTime=2020-01-03, rootId=0, userName=chenzhuanggui, userId=7c123763345, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=07da185565a3, moduleTitle=Blood： CD19特异性CAR T细胞疗法治疗R/R B-ALL, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=07da185565a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1423252, encodeId=c28a14232528e, content=<a href='/topic/show?id=18f43131be' target=_blank style='color:#2F92EE;'>#B-ALL#</a>, objectTitle=Blood：CD19特异性CAR T细胞疗法治疗R/R B-ALL, objectType=article, longId=181713, objectId=584d181e139f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=584d181e139f, replyNumber=0, likeNumber=104, createdTime=2019-10-23, rootId=0, userName=chenzhuanggui, userId=7c123763345, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=584d181e139f, moduleTitle=Blood：CD19特异性CAR T细胞疗法治疗R/R B-ALL, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=584d181e139f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1423251, encodeId=b93d1423251e7, content=<a href='/topic/show?id=18f43131be' target=_blank style='color:#2F92EE;'>#B-ALL#</a>, objectTitle=Leukemia：难治性或复发性B-ALL：低剂量CD19-CAR-T细胞疗法有效吗？, objectType=article, longId=130441, objectId=33e2130441cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=33e2130441cc, replyNumber=0, likeNumber=81, createdTime=2018-02-25, rootId=0, userName=chenzhuanggui, userId=7c123763345, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=33e2130441cc, moduleTitle=Leukemia：难治性或复发性B-ALL：低剂量CD19-CAR-T细胞疗法有效吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=33e2130441cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1423250, encodeId=f296142325071, content=<a href='/topic/show?id=18f43131be' target=_blank style='color:#2F92EE;'>#B-ALL#</a>, objectTitle=Blood：通过高通量测序检测残留病灶，可改善儿童B-ALL的危险分层。, objectType=article, longId=125159, objectId=354412515978, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=354412515978, replyNumber=0, likeNumber=135, createdTime=2018-01-01, rootId=0, userName=chenzhuanggui, userId=7c123763345, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=354412515978, moduleTitle=Blood：通过高通量测序检测残留病灶，可改善儿童B-ALL的危险分层。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=354412515978)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1423249, encodeId=211b14232497f, content=<a href='/topic/show?id=18f43131be' target=_blank style='color:#2F92EE;'>#B-ALL#</a>, objectTitle=J Clin Oncol：高危B-ALL患者来说，接受大剂量甲氨蝶呤治疗可更好地改善其生存率, objectType=article, longId=74192, objectId=da19e419235, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=da19e419235, replyNumber=0, likeNumber=50, createdTime=2016-08-02, rootId=0, userName=chenzhuanggui, userId=7c123763345, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=da19e419235, moduleTitle=J Clin Oncol：高危B-ALL患者来说，接受大剂量甲氨蝶呤治疗可更好地改善其生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=da19e419235)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

B-ALL

2020-05-29

chenzhuanggui (审核中...)

前往app查看评论内容

#B-ALL#

Blood：尼洛替尼联合PD-L1阻滞可逆转CD4+T细胞耗竭预防B-ALL复发

2022-08-21

chenzhuanggui (审核中...)

前往app查看评论内容

#B-ALL#

Blood：采用CD19/22 CAR T细胞治疗儿童和年轻成人B-ALL

2022-08-12

chenzhuanggui (审核中...)

前往app查看评论内容

#B-ALL#

J Clin Oncol：博纳吐单抗诱导巩固+POMP维持治疗Ph染色体阴性B-ALL老年患者的疗效

2022-02-20

chenzhuanggui (审核中...)

前往app查看评论内容

#B-ALL#

J Clin Oncol：博纳吐单抗无反应和高疾病负荷提示，B-ALL患者采用CD19-CAR治疗的预后不良

2021-11-19

chenzhuanggui (审核中...)

前往app查看评论内容

#B-ALL#

Nat Med：双重靶向CART细胞对复发或难治性B-ALL儿童和年轻成人患者疗效分析

2021-10-16

chenzhuanggui (审核中...)

前往app查看评论内容

#B-ALL#

Blood：分子分类可改善BCR-ABL1阴性B-ALL成人患者的风险评估

2021-09-26

chenzhuanggui (审核中...)

前往app查看评论内容

#B-ALL#

J Clin Oncol：新型二代CD19-CAR T细胞治疗复发/难治性B-ALL成人患者的效果和安全性

2021-09-03

chenzhuanggui (审核中...)

前往app查看评论内容

#B-ALL#

Blood：抗CD19 CAR T细胞治疗后病情进展的B-ALL成人患者的干预措施和临床预后

2021-08-28

chenzhuanggui (审核中...)

前往app查看评论内容

#B-ALL#

J Clin Oncol：人源CD19 CAR T细胞可使复发或难治性B-ALL患者获得持久的缓解

2021-06-26

chenzhuanggui (审核中...)

前往app查看评论内容

#B-ALL#

Bone Marrow Transplant：供体源性抗CD19的CAR-T细胞疗法可安全有效的治疗异体造血干细胞移植后复发的B-ALL

2021-05-03

chenzhuanggui (审核中...)

前往app查看评论内容

#B-ALL#

Blood：影响B-ALL患者博纳吐单抗治疗效果的肿瘤内外标志物

2020-09-17

chenzhuanggui (审核中...)

前往app查看评论内容

#B-ALL#

Blood：IKAROS和CK2调控高危型B-ALL的BCL-XL表达和化疗敏感性

2020-06-05

chenzhuanggui (审核中...)

前往app查看评论内容

#B-ALL#

Blood：B-ALL超二倍体细胞有丝分裂和染色体缺陷的分子机制

2020-05-04

chenzhuanggui (审核中...)

前往app查看评论内容

#B-ALL#

Blood：减小低复发风险B-ALL患儿的化疗强度可改善预后

2020-02-10

chenzhuanggui (审核中...)

前往app查看评论内容

#B-ALL#

Blood： CD19特异性CAR T细胞疗法治疗R/R B-ALL

2020-01-03

chenzhuanggui (审核中...)

前往app查看评论内容

#B-ALL#

Blood：CD19特异性CAR T细胞疗法治疗R/R B-ALL

2019-10-23

chenzhuanggui (审核中...)

前往app查看评论内容

#B-ALL#

Leukemia：难治性或复发性B-ALL：低剂量CD19-CAR-T细胞疗法有效吗？

2018-02-25

chenzhuanggui (审核中...)

前往app查看评论内容

#B-ALL#

Blood：通过高通量测序检测残留病灶，可改善儿童B-ALL的危险分层。

2018-01-01

chenzhuanggui (审核中...)

前往app查看评论内容

#B-ALL#

J Clin Oncol：高危B-ALL患者来说，接受大剂量甲氨蝶呤治疗可更好地改善其生存率

2016-08-02

科室
- - 订阅+
  - 更多科室
工具
服务